Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Position Increased by Vestal Point Capital LP

Vestal Point Capital LP grew its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 1.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 850,000 shares of the company’s stock after purchasing an additional 10,000 shares during the period. Vestal Point Capital LP owned approximately 2.57% of Lexeo Therapeutics worth $7,684,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Lexeo Therapeutics by 15.8% in the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock valued at $7,554,000 after acquiring an additional 65,573 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Lexeo Therapeutics by 107.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock valued at $577,000 after purchasing an additional 33,013 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Lexeo Therapeutics by 12.3% during the second quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock valued at $510,000 after purchasing an additional 3,483 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Lexeo Therapeutics by 121.5% in the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after purchasing an additional 7,803 shares during the period. Finally, Rhumbline Advisers grew its position in Lexeo Therapeutics by 37.3% in the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after buying an additional 3,627 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LXEO shares. Leerink Partners reduced their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Wednesday, November 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th. Chardan Capital upped their price objective on Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright boosted their price target on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $23.80.

Lexeo Therapeutics Price Performance

Shares of NASDAQ LXEO opened at $7.83 on Friday. The stock’s fifty day simple moving average is $8.43 and its 200 day simple moving average is $11.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics, Inc. has a 52-week low of $5.77 and a 52-week high of $22.33.

Insider Buying and Selling

In related news, CEO Richard Nolan Townsend sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $10.65, for a total value of $53,250.00. Following the completion of the transaction, the chief executive officer now owns 120,695 shares of the company’s stock, valued at approximately $1,285,401.75. This trade represents a 3.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 12,500 shares of company stock valued at $113,300. 4.50% of the stock is owned by corporate insiders.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.